论文部分内容阅读
目的探讨阿奇霉素针对成人支原体肺炎(MP)的临床疗效及不良反应反生情况。方法回顾性分析本院2009年4月-2011年1月收治的56例成人支原体肺炎患者,随机分为治疗组给用阿奇霉素组30例及给用红霉素组26例,比较两组治疗前后的肺部体征的变化及不良反应。结果阿奇霉素组显效率为73.3%,总有效率为93.3%,红霉素组显效率为38.5%,总有效率为69.3%,两组之间比较具有显著性差异(P<0.01);阿奇霉素组不良反应共9例,红霉素组不良反应共21例,两组皮疹发生率比较无显著性差异(P>0.05);局部静脉疼痛比较有差异(P<0.01);胃肠道反应两组比较具有显著性差异(P<0.05)。结论阿奇霉素治疗成人支原体肺炎疗效确切,使用方便、安全,不良反应发生率低,有临床推广使用的价值。
Objective To investigate the clinical efficacy and adverse reactions of azithromycin against adult mycoplasma pneumonia (MP). Methods A retrospective analysis of 56 patients with mycoplasma pneumonia admitted in our hospital from April 2009 to January 2011 were randomly divided into treatment group treated with azithromycin 30 cases and erythromycin group 26 cases treated before and after treatment Changes in lung signs and adverse reactions. Results The effective rates of azithromycin group was 73.3%, the total effective rate was 93.3%, the effective rate of erythromycin group was 38.5%, the total effective rate was 69.3%, there was a significant difference between the two groups (P <0.01) There were 9 cases of adverse reactions, 21 cases of erythromycin adverse reactions, there was no significant difference in the incidence of rash between the two groups (P> 0.05), local venous pain was significantly different (P <0.01), gastrointestinal reactions in both groups Compared with significant difference (P <0.05). Conclusion Azithromycin treatment of adult mycoplasma pneumonia curative effect is exact, easy to use, safe, low incidence of adverse reactions, the clinical application of the value.